Novartis IBS therapy
FDA and Novartis have agreed to the trade name Zelnorm for the irritable bowel syndrome agent tegaserod (formerly Zelmac). FDA requested a new name based on the potential for confusion with other brands. The user fee review deadline for Zelnorm is in June
You may also be interested in...
Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011